National Jewish Health is dedicated to medical research and treatment of patients with respiratory, cardiac, immune, and related disorders.

National Jewish Health

National Jewish Health is dedicated to medical research and treatment of patients with respiratory, cardiac, immune and related disorders.

Hospitals and Health Care

National Jewish Health Advanced Diagnostic Laboratories

Health, Wellness & Fitness

QuitLogix Tobacco Cessation Program

Wellness & Prevention Programs

National Jewish Health | 10,649 followers on LinkedIn. Breathing Science is Life | For more than 125 years, National Jewish Health has been at the forefront of research and medicine. We integrate the latest scientific discoveries with coordinated care for pulmonary, cardiac, immune and related conditions. National Jewish Health physicians and researchers are at the forefront of a new era in health care that embraces a personalized, preventive approach to medicine.

Robert Poole

Vice President of Technology or Software Engineering

Chris Toomer

Andrea Harshman, MHA, CHCP, CMP-HC

Julia Henderson

Early bird registration ends on Dec. 5. Secure your spot at the lowest price and prepare to elevate your expertise at the 47th Annual Pulmonary and Allergy Update, Feb 5-8, 2025. https://brnw.ch/21wOP42 The Pulmonary and Allergy Update offers a unique opportunity to gain insights into recent advances in pulmonary medicine, asthma, allergy, and immunology, guided by expert faculty from the nation’s leading respiratory hospital. Connect with colleagues and nationally recognized experts while exploring the latest updates on patient management and treatment options. Interactive workshops and small-group sessions provide an excellent forum to discuss key issues and challenging cases with peers and faculty from National Jewish Health, enhancing your knowledge and practical skills in a collaborative learning environment.

About 130 million adults in the U.S. have some form of #heartdisease , which, according to the American Heart Association puts them at greater risk for #dementia . Cardiologist Andrew Freeman, MD, comments on the link between the head and #heart in this story by CNN . https://brnw.ch/21wOL5Z

Cases of #whooping #cough in Colorado have tripled since last year, putting young #children at risk. Pulmonologist Tod Olin, MD, explains the potential reasons behind this increase and how you can protect loved ones in this story by CBS News. https://brnw.ch/21wOJ4J

Whether it's the dry air or piles of leaves, #fall presents unique challenges for people with #allergies . Pulmonologist David Beuther, MD, explains why these conditions can contribute to #headaches and respiratory illnesses in this story by FOX31 KDVR / Channel 2 KWGN . https://brnw.ch/21wOIGb

If you experience #dizziness or #lightheadedness after standing up, you may have orthostatic hypotension. Cardiologist Minisha Kochar, MD, explains what's behind the decline in #bloodpressure that causes these symptoms in this story by Health Central. https://brnw.ch/21wOHNi

Join Dr. Jennifer Taylor-Cousar, Dr. Jered Eddy, and Sara Dederman Brayshaw to learn why diagnoses of cystic fibrosis continue to be missed both in infancy and later into adolescence and adulthood and how health professionals can improve their ability to spot CF in patients to improve care. Missed or delayed diagnoses of CF and CFTR-related disorders can have important implications for disease progression and health outcomes. Participants in this program will increase their awareness about missed diagnoses of CF, examine factors that lead to missed diagnoses including race, rare mutations and pancreatic sufficiency, and analyze options for patient testing and treatment of suspected CF and CFTR-related disorders. 1.0 CME/CNE earned for completing this free course https://brnw.ch/21wOqfU

The discovery of the mechanisms of type 2 (T2) inflammation in #asthma gave rise to #biologic therapies that have dramatically expanded treatment options for patients with moderate-to-severe eosinophilic or allergic asthma. Newly approved and emerging therapies that target the epithelial alarmins represent an important opportunity to improve outcomes for patients with a broad range of asthma phenotypes. In this activity, Drs. Rohit Katial, Eileen Wang and Michael Wechsler, provide insights into the new paradigm of treatments and how to manage the complexity of severe asthma treatment. This program will focus on the role of epithelial alarmins in the inflammatory cascade of asthma, and connecting clinical characteristics to patients’ biomarkers for treatment. Topics include: current challenges in severe asthma management; the pathophysiology of severe asthma; targets for current and emerging treatments; and selecting treatments based on patient phenotypes. 1.0 CME earned for completing this free course https://bit.ly/NJHAsthma23

If the upcoming #election is stressing you out, it might be a good time to learn new healthy #stress reduction habits. Cardiologist Andrew Freeman, MD, comments on the calming effects of #nature in this story by CNN . https://brnw.ch/21wOlt5

The effects of #eczema are more than skin-deep. Pediatric allergist and immunologist Jessica Hui, MD, discusses some of the non-visible #challenges of people with eczema and how to manage them in this interview with Dermatology Times . #dermatology https://brnw.ch/21wOjvw

The discovery of the mechanisms of type 2 (T2) inflammation in #asthma gave rise to #biologic therapies that have dramatically expanded treatment options for patients with moderate-to-severe eosinophilic or allergic asthma. Newly approved and emerging therapies that target the epithelial alarmins represent an important opportunity to improve outcomes for patients with a broad range of asthma phenotypes. In this activity, Drs. Rohit Katial, Eileen Wang and Michael Wechsler, provide insights into the new paradigm of treatments and how to manage the complexity of severe asthma treatment. This program will focus on the role of epithelial alarmins in the inflammatory cascade of asthma, and connecting clinical characteristics to patients’ biomarkers for treatment. Topics include: current challenges in severe asthma management; the pathophysiology of severe asthma; targets for current and emerging treatments; and selecting treatments based on patient phenotypes. https://bit.ly/NJHAsthma23

NATI

ORG:NATIONALJEWISH

National Jewish Health